1-5 of 5
Fredrick O. Onono
Close
Sort by
Journal Articles

Modulation of Anthracycline-Induced Cytotoxicity by Targeting the Prenylated Prenylome in Myeloid Leukemia Cells

Michael A Morgan, PhD, Fredrick O Onono, Peter H Spielmann, Thangaiah Subramanian, Michaela Scherr, Letizia Venturinin, Iris Dallmann, Arnold Ganser, MD, Christoph W.M. Reuter
Journal: Blood
Blood (2011) 118 (21): 1418.
https://doi.org/10.1182/blood.V118.21.1418.1418
Published: 2011
Journal Articles

A Novel Proteomic Approach to Define Leukemia Cell Resistance to Farnesyltransferase Inhibitors.

Fredrick O. Onono, Ph.D., Michael A. Morgan, Ph.D., H. Peter Spielmann, Ph.D., Douglas A Andres, Ph.D., Michaela Scherr, Ph.D., Letizia Venturini, Ph.D., Iris Dallman, Arnold Ganser, MD, Christoph WM Reuter, M.D., Ph.D.
Journal: Blood
Blood (2009) 114 (22): 3761.
https://doi.org/10.1182/blood.V114.22.3761.3761
Published: 2009
Journal Articles

The Farnesyltransferase Inhibitor (FTI) L-778,123 Displays Promising Anti-Leukemia Activity

Fredrick O. Onono, Michael A. Morgan, Ph.D., Arnold Ganser, M.D., Ph.D., Christoph W. M. Reuter, M.D., Ph.D.
Journal: Blood
Blood (2008) 112 (11): 2627.
https://doi.org/10.1182/blood.V112.11.2627.2627
Published: 2008
Journal Articles

Potentiation of Topoisomerase II Inhibitor-Mediated Myeloid Leukemia Cell Kill by Farnesyltransferase Inhibitor L-744,832.

Fredrick O. Onono, MSc, Michael A. Morgan, PhD, Jeanny Wegner, MD, Arnold Ganser, MD/PhD, Christoph W.M. Reuter, MD/PhD
Journal: Blood
Blood (2007) 110 (11): 3479.
https://doi.org/10.1182/blood.V110.11.3479.3479
Published: 2007
Journal Articles

Characterization of a Novel R-RAS Mutation Cloned from Primary AML Cells.

Christoph W.M. Reuter, MD, PhD, Erdem Aydilek, MD, Fredrick O. Onono, Michael A. Morgan, PhD, Kristine A. Henningfeld, PhD, Arnold Ganser, MD/PhD
Journal: Blood
Blood (2006) 108 (11): 1439.
https://doi.org/10.1182/blood.V108.11.1439.1439
Published: 2006